Antares Pharma, Inc. AIS today announced plans to conduct a clinical trial of the Company's proprietary VIBEX™ MTX product being developed for the treatment of rheumatoid arthritis following clearance of an Investigational New Drug application filed with the U.S. Food and Drug Administration on December 8, 2010.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
